Seed, 2021
diagnosis for neurodevelopmental disorders is achievable with a simple blood test.
AIF is building a world where
September, 2021
behavioral therapy is clinically validated and data-driven.
AIF is building a world where
Series C, 2021
microbiome-targeted therapeutics exist to improve nervous system function.
AIF is building a world where
Seed, 2021
care for individuals with disabilities is accessible.
AIF is building a world where
Series A, 2021
therapeutics exist to address core symptoms of neurological conditions.
AIF is building a world where
Seed, 2021
therapy for behavioral conditions is affordable and tech-enabled.
AIF is building a world where
Bridge, 2021
where chronic health conditions are manageable through precision nutrition.
AIF is building a world where
Growth, 2021
employment opportunities for neurodiverse individuals are plentiful.
AIF is building a world where
Strategic, 2022
care for neurological conditions is comprehensive, outcomes-based, and led by doctors.
AIF is building a world where
Bridge, 2022
wait times for ASD diagnoses is zero.
AIF is building a world where
Seed, 2022
precision medicine tools exist to detect and treat core ASD symptoms.
AIF is building a world where
LATEST NEWS
Auticon and Unicus Join Forces, Advancing ESG Mission of Neurodiversity
Auticon / June 14, 2023
Autism Care Provider Cortica Raises $75M, Acquires 2 Provider Groups in New England, Arizona
Fierce Healthcare / April 18, 2023
OUR MISSION
AIF’s bold mission is to revolutionize the status quo for diagnosing, treating, and living with autism spectrum disorder (ASD), neurodevelopmental disorders, mental health issues, and complex chronic conditions through a venture capital model that helps accelerate developing and delivering emerging technologies, translational science, and innovative services to empower individuals to reach their full potential.
OUR VALUES
We identify unmet needs across the continuum of ASD and related conditions and deploy venture capital to invent, develop, and fuel solutions that address those needs.
Seed, 2021
diagnosis for
neurodevelopmental
disorders is achievable
with a simple blood test.
AIF is building a world where
September, 2021
behavioral intervention
is clinically validated
and data-driven.
AIF is building a world where
Series C, 2021
microbiome-targeted
therapeutics exist to
improve nervous
system function.
AIF is building a world where
Seed, 2021
care for individuals with
disabilities is accessible.
AIF is building a world where
Series A, 2021
treatments are safe,
effective, and well-tolerated.
AIF is building a world where
Seed, 2021
therapy for behavioral
conditions is affordable
and tech-enabled.
AIF is building a world where
Bridge, 2021
where chronic health
conditions are manageable
through precision nutrition.
AIF is building a world where
Growth, 2021
employment opportunities
for neurodiverse individuals
are plentiful.
AIF is building a world where
Strategic, 2022
care for neurological
conditions is comprehensive,
outcomes-based, and
led by doctors.
AIF is building a world where
Seed, 2022
precision medicine tools
exist to detect and treat
core ASD symptoms.
AIF is building a world where
LATEST NEWS
Auticon and Unicus Join Forces, Advancing ESG Mission of Neurodiversity
Auticon / June 14, 2023
Autism Care Provider Cortica Raises $75M, Acquires 2 Provider Groups in New England, Arizona
Fierce Healthcare / April 18, 2023
OUR MISSION
AIF’s bold mission is to revolutionize the status quo for diagnosing, treating, and living with autism spectrum disorder (ASD), neurodevelopmental disorders, mental health issues, and complex chronic conditions through a venture capital model that helps accelerate developing and delivering emerging technologies, translational science, and innovative services to empower individuals to reach their full potential.
OUR VALUES
We identify unmet needs across the continuum of ASD and related conditions and deploy venture capital to invent, develop, and fuel solutions that address those needs.
AS SEEN ON
